São Paulo, January 20 – Eurofarma, one of the largest pharmaceutical companies in Latin America, participated in the event "Brazil 2030: Health and Consumption – Trends, Innovation, and the Future of the Sector," held on January 20 in São Paulo by Times Brasil CNBC. The meeting brought together public authorities, such as the Minister of Health, Alexandre Padilha, and the president of the National Health Surveillance Agency (Anvisa), Leandro Safatle, as well as executives from major companies, to debate the challenges and opportunities in the healthcare sector, addressing themes such as trends, innovation, system sustainability, access to health, and the paths shaping the future of the sector in Brazil.

During the panel “Pharmaceutical Industry, Production, and System Sustainability,” Walker Lahmann, Executive Director of Institutional Relations at Eurofarma, reinforced the strategic role of the national pharmaceutical industry and the sector's leadership in innovation investments. According to him, the pharmaceutical sector is currently the one that invests the most in innovation in Brazil, driving research, technology, and scientific development. He highlighted Eurofarma as one of the main examples of this movement: “Today we have more than 750 scientists working at EuroLab, our innovation laboratory—an environment dedicated to technological development, advanced research, and the creation of solutions that expand access to health and strengthen the industry's competitiveness,” stated Lahmann.

Furthermore, during the panel, the executive also highlighted Brazil's relevance in medicine production. Currently, the country manufactures about 70% of the medicines consumed in the domestic market, a rate higher than that recorded in economies such as the United States and European countries, reflecting the robustness of the Brazilian pharmaceutical industry's installed capacity. Leandro Berbert, partner and leader of Health Sciences and Wellness at EY Brazil, and Bruno Sobral, executive director of FENASAÚDE, also participated in the debate, contributing to the discussion on innovation in the sector and addressing themes of great relevance to society, such as the race for GLP-1 medications, in addition to other health challenges and trends.

About Eurofarma
Founded in 1972, Eurofarma operates in the health sector with the production and marketing of products and services to improve people's quality of life. With a focus on generating shared value, it covers the main pharmaceutical segments, such as medical prescription, generics, hospital, oncology, OTC, personal care, and animal health, in addition to providing production services to third parties. With broad coverage of therapeutic classes, the portfolio comprises more than 4,000 SKUs, serving practically all medical specialties. Leader in medical prescription in Brazil, where it also holds the vice-leadership in generics, Eurofarma is present in 24 countries, with 100% coverage in Latin America and leadership in the region's retail. It also maintains operations in the USA and Africa, counting in total more than 13.5 thousand employees and 11 factories, and accounted for 600 million units produced in 2024. In the same year, the company invested more than R$ 800 million in innovation projects and achieved net revenue exceeding R$ 11 billion.

Press Information
G&A Relações Públicas
e-mail: imprensaeurofarma@gaspar.com.br
Iza França - 11 97644-4496 (iza.franca@gaspar.com.br)
Guilherme Gaspar - 11 98285-6000